News

SynDermix Announces Interim Changes to Leadership 20 May, 2020

Delegate of the Board and Chief Executive Officer of SynDermix AG, Mr. Dieter Hemmer, on medical leave of absence; Dr. Konstantinos Efthymiopoulos appointed Designated Managing Director until the AGM 2020
(more…)

Update on the Clinical Trial of the SDX-3101 Medical Device 7 April, 2020

SynDermix AG announced temporary postponement of initiation of the SDX-3101 clinical trial on chronic rhinosinusitis without nasal polyps due to the novel coronavirus pandemic. (more…)

First Site Initiation Visit (SIV) Completed for the Clinical Trial of SDX-3101 in Austria 7 January, 2020

SynDermix AG is pleased to announce the successful completion of the first SIV for the clinical trial of SDX-3101, in preparation for the recruitment of the first patient to the study. (more…)

Collaboration with King’s College London on the Formulation Development of SDX-21 1 July, 2019

SynDermix AG is proud to announce its collaboration with King’s College London for the development of its Nitric Oxide technology. (more…)

AGM 2019: Re-election of Chairman and Board of Directors 11 June, 2019

Shareholders approve all proposals put forward by the Board of Directors and re-elect the Chairman and Directors to the board of SynDermix.
(more…)

SynDermix to Sell Majority Stake of SDX-Cosmetics 10 April, 2019

SynDermix announces the sale of a majority stake of SDX Cosmetics – formerly a fully owned subsidiary of SynDermix AG. (more…)

SynDermix Announces Changes to the Executive Team 1 April, 2019

The Board of SynDermix announces changes in the management and executive team. (more…)

Share Capital Increased 14 March, 2019

The Board of Directors announces a successful increase of share capital: A total of CHF 1 000 000 in loans were converted against 232 222 newly issued shares.

CHF 10 Million Investment 19 December, 2018

The Board of SynDermix is pleased to announce the closure of a new investment of CHF 10 million in the Company as of December 2018. The Company plans to use the proceeds to fund operations, product development and future potential acquisitions.

SDX-3103 Kick-Off Meeting, Biel 25 October, 2018

SynDermix announces the successful kick-off meeting of the project SDX-3103 (more…)